Research location

Arlington Heights

Illinois, United States

Published trials149

Site observations149

Linked trials published149

Page1 / 3

Research activity in Arlington Heights

Illinois, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 149 trials and 149 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Arlington Heights

149 linked trials · page 1 of 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation

E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20 · 1 site observation

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112 · 2025-03-27 · 1 site observation

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · 2024-06-17 · 1 site observation

Study of ORIC-944 in Patients With Metastatic Prostate CancerNCT05413421 · 2022-06-01 · 1 site observation

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation

A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · 2025-11-17 · 1 site observation

ACTIVE_NOT_RECRUITING

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)NCT06773910 · 2025-03-11 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · 2024-02-21 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08 · 1 site observation

ACTIVE_NOT_RECRUITING

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXNCT05467176 · 2022-10-04 · 1 site observation

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsNCT05074810 · 2022-04-12 · 1 site observation

ACTIVE_NOT_RECRUITING

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid TumorsNCT05001347 · 2021-11-02 · 1 site observation

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionNCT05001945 · 2021-07-01 · 1 site observation

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNCT04916470 · 2021-06-15 · 1 site observation

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557 · 2021-04-20 · 1 site observation

Breast Cancer Index (BCI) RegistryNCT04875351 · 2021-04-14 · 1 site observation

ACTIVE_NOT_RECRUITING

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and ObesityNCT04788511 · 2021-03-16 · 1 site observation

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)NCT04519658 · 2020-10-12 · 1 site observation

Breast Cancer Liquid Biopsy TrialNCT04962529 · 2020-09-28 · 1 site observation

TTX-080 HLA-G Antagonist in Subjects With Advanced CancersNCT04485013 · 2020-07-14 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)NCT03888066 · 2019-04-24 · 1 site observation

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection FractionNCT03877224 · 2019-04-04 · 1 site observation

Mylan Insulin Aspart StudyNCT03760068 · 2018-11-07 · 1 site observation

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT03563716 · 2018-08-10 · 1 site observation

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation

Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.NCT03448406 · 2018-03-20 · 1 site observation

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure SymptomsNCT03448419 · 2018-03-20 · 1 site observation

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143 · 2017-12-19 · 1 site observation

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)NCT02574455 · 2017-11-07 · 1 site observation

Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke CigarettesNCT02856581 · 2017-09-29 · 1 site observation

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsNCT03066804 · 2017-08-22 · 1 site observation

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlNCT03242018 · 2017-08-16 · 1 site observation

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin GlargineNCT03211858 · 2017-08-02 · 1 site observation

Feasibility of a Technology-Based Treatment Support SystemNCT03121937 · 2017-08-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.